【摘要】 目的　验证奥氮平治疗精神分裂症的疗效和安全性。方法　对６５ 例精神分裂症患者予以奥氮平在５～２０ ｍｇ／ｄ 治疗， 疗程为６ 周。采用阳性与阴性症状量表以及简明精神病评定量表（ＢＰＲＳ） 评定疗效；采用不自主运动量表、ＳｉｍｐｓｏｎＡｎｇｕｓ 量表和副反应量表评定不良反应。结果　６５例中脱落３ 例（ 在临床疗效评定中按无效计）；完成治疗的６２ 例中完全缓解５２％ （３４／６５），显著进步２８ ％（１８／６５） ，进步８％ （５／６５） ，无效１２％ （８／６５） 。奥氮平对阳性、阴性症状以及一般精神病态均有良好疗效。该药锥体外系不良反应少。主要不良反应为抗胆碱作用、困倦、体重增加、一过性肝酶活性升高等。结论　奥氮平是一种安全有效、服用方便的新型抗精神病药更多还原

【Abstract】 Objective The purpose of this study was to observe the efficacy and safety of olanzapine in the treatment of schizophrenia Methods 65 patients with schizophrenia were included in this 6 weeks open trail clinical study The Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) derived from the PANSS were used to assess the clinical efficacy and the Abnormal Involuntary Movement Scale (AIMS), Simpson Angus Scale (SAS), and Treatment Emergent Side effect Scale (TESS) were used to assess the adverse effects Results Sixty two cases completed the 6 weeks treatment while 3 dropped out Among the 65 patients, 52% (34/65) met the criteria of complete relief, 28% (18/65) markedly improved, 8% (5/65) improved, and 12% (8/65) got no change The drug showed good effect on the positive, negative, as well as general psychopathological symptoms of schizophrenia Olanzapine showed low extrapyramidal symptoms during treatment The main adverse effects included anticholinergic effects, drowsiness, weight gain, and transient increase of liver enzymes, etc Conclusions The study suggests that olanzapine are a safe, effective antipsychotic agent with convenient dosing regime更多还原